P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY

• K. Weisel,
• S. Kumar,
• P. Moreau,
• N. Bahlis,
• T. Facon,
• T. Plesner,
• R. Orlowski,
• S. Basu,
• H. Nahi,
• C. Hulin,
• H. Quach,
• H. Goldschmidt,
• M. O’Dwyer,
• A. Perrot,
• C. Venner,
• N. Raje,
• M. Tiab1,
• M. Macro,
• L. Frenzel,
• X. Leleu,
• H. Pei,
• M Krevvata,
• R Carson,
• F. Borgsten,
• S. Usmani

Affiliations

K. Weisel

1 Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

S. Kumar

2 Department of Hematology, Mayo Clinic Rochester, Rochester, NY, USA

P. Moreau

3 Hematology Department, University Hospital Hôtel-Dieu, Nantes, France

N. Bahlis

4 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB

T. Facon

5 University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

T. Plesner

6 Vejle Hospital and University of Southern Denmark, Vejle, Denmark

R. Orlowski

7 Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

S. Basu

8 Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, United Kingdom

H. Nahi

9 Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden

C. Hulin

10 Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France

H. Quach

11 University of Melbourne, St Vincent’s Hospital, Melbourne, Australia

H. Goldschmidt

12 University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany

M. O’Dwyer

13 Department of Medicine/Haematology, NUI, Galway, Ireland

A. Perrot

14 CHU de Toulouse, IUCT-O, Université de Toulouse, Toulouse, France

C. Venner

15 Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB

N. Raje

17 Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA

M. Tiab1

8 Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, United Kingdom

M. Macro

19 Centre Hospitalier Universitaire (CHU) de Caen, Caen, France

L. Frenzel

20 Hôpital Necker-Enfants Malades, Paris, France

X. Leleu

21 CHU Poitiers, Hôpital la Milétrie, Poitiers, France

H. Pei

22 Janssen Research & Development, LLC, Titusville, PA

M Krevvata

23 Janssen Research & Development, LLC, Spring House, PA

R Carson

23 Janssen Research & Development, LLC, Spring House, PA

F. Borgsten

24 Janssen Research & Development, LLC, Raritan, NJ

S. Usmani

25 Memorial Sloan Kettering Cancer Center, New York, NY